Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Lymphoma
•
Myeloma
•
Internal Medicine
•
Hematology
What would your next line of therapy be for a young patient with Waldenstrom's Macroglobulinemia (MYD88 and CXCR wild type) with hyperviscosity who did not have a response to Bendamustine/Rituximab?
Related Questions
How do you discuss harms of MGUS screening with other medical providers?
How would you manage a pre-menopausal woman with extranodal marginal zone lymphoma confined to the bladder wall?
How would you manage a patient with symptomatic low grade leukemic NHL w/o a clear diagnosis of either FL or MZL?
For a patient with ENKTL nasal type (nose/sinus involvement) who has hepatic toxicity with pegasparaginase but a CR after 2 cycles of chemotherapy with a plan for "sandwich" radiotherapy - what, if any, chemotherapy would you resume after completion of radiation?
How would you manage a case of subcutaneous panniculitis-like T cell lymphoma (A/B) who is already on steroids and methotrexate for autoimmune disease?
How would you manage a young, HIV-negative patient with good performance status with primary refractory Burkitt Lymphoma involving the CNS and systemic disease?
How do you evaluate a patient with MGUS and peripheral neuropathy?
How does one interpret an SPEP showing potentially obscured but non-quantifiable M-spike however an IFE showing monoclonal protein?
Does the presence of osteoporosis change the extent of workup that should be performed for an older patient with otherwise serologically low-risk MGUS?
For otherwise transplant-eligible patients with myeloma, given developments of bispecifics and CAR-T, what is your age cutoff for consolidative autologous transplant?
